People · Operator
Named in public records as an officer, director or promoter · active 2015–2019 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Quadrant Biosciences Inc | — | Biotechnology | Series B | $37.4M | $241.1M | 2015 |
David MacLean at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David MacLean on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Andrew Rock | 1 | 4 |
| Peter Cohen | 1 | 3 |
| Patrick Bailey | 1 | 2 |
| Richard K. Bongo | 1 | 1 |
| Cindy Dowd Greene | 1 | 1 |
| Ira Dowd Fedder | 1 | 1 |
| Erica Ash | 1 | 1 |
| James Croke | 1 | 1 |
| Richard Bongo | 1 | 1 |
| Nicholas Gianadda | 1 | 1 |
| Ira Fedder | 1 | 1 |
| Mary Ann Tyszko | 1 | 1 |
| Bryan Greene | 1 | 1 |
| Wade West | 1 | 1 |
| Chris Horacek | 1 | 1 |
| Scott Giambalvo | 1 | 1 |
| Alexander Rajan | 1 | 1 |
| Kayla Wagner | 1 | 1 |
| Andrew Brindle | 1 | 1 |
| Randy Carpenter | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.